SCHEMBL4672298

SCHEMBL4672298

O=C(C=C(O)c1nc[nH]n1)c1coc(Cc2ccc(Cl)cc2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
POLB P06746 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
APLNR P35414 1/20 0.32
KDM4C Q9H3R0 3/20 0.32
KDM5B Q9UGL1 2/20 0.32
KDM4A O75164 1/20 0.32
SMPD1 P17405 1/20 0.32
LMNA P02545 1/20 0.32
HSD17B10 Q99714 1/20 0.32
NR4A2 P43354 2/20 0.31
IDH1 O75874 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
DAO P14920 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672199 0.91 IDH1 (0.40) IDH1DAO
SCHEMBL4678236 0.91 LMNA (0.34) SMN1; SMN2KDM4EALDH1A1POLBKDM4C
SCHEMBL4677449 0.91 RECQL (0.33) SMN1; SMN2ALDH1A1CYP1A2CYP2C19KDM4C
SCHEMBL4678867 0.91 IDH1 (0.30) IDH1
SCHEMBL4670555 0.90 KMT2A (0.36) SMN1; SMN2KDM4EALDH1A1CYP1A2POLB
SCHEMBL4675429 0.89 IDH1 (0.31) LMNAIDH1
SCHEMBL4679964 0.89 HCAR2 (0.39) ALDH1A1KDM4CKDM5BKDM4ALMNA
SCHEMBL4674403 0.89 ALDH1A1 (0.37) SMN1; SMN2KDM4EALDH1A1POLBKDM5B
SCHEMBL4671358 0.88 SRD5A2 (0.36) KDM4EAPLNRKDM4CKDM5BKDM5A
SCHEMBL4674476 0.85 NR4A2 (0.33) ALDH1A1POLBKDM4CKDM5BKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 SMN1; SMN2 4107/4885KDM4E 947/4885ALDH1A1 980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.